Fate Therapeutics - FATE Stock Forecast, Price & News

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" FATE shares.
View FATE analyst ratings or view top-rated stocks.

12 brokerages have issued 1-year price targets for Fate Therapeutics' stock. Their FATE share price forecasts range from $28.00 to $115.00. On average, they expect the company's stock price to reach $65.27 in the next twelve months. This suggests a possible upside of 244.2% from the stock's current price.
View analysts price targets for FATE or view top-rated stocks among Wall Street analysts.

Fate Therapeutics' stock was trading at $58.51 on January 1st, 2022. Since then, FATE shares have decreased by 67.6% and is now trading at $18.96.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our FATE earnings forecast.

Fate Therapeutics, Inc. (NASDAQ:FATE) announced its quarterly earnings data on Thursday, November, 4th. The biopharmaceutical company reported ($0.45) EPS for the quarter, beating analysts' consensus estimates of ($0.58) by $0.13. The biopharmaceutical company had revenue of $14.23 million for the quarter, compared to the consensus estimate of $8.67 million. Fate Therapeutics had a negative net margin of 425.99% and a negative trailing twelve-month return on equity of 48.78%. The firm's revenue was up 88.3% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.36) earnings per share.

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD).

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (12.02%), BlackRock Inc. (8.15%), Vanguard Group Inc. (8.04%), State Street Corp (4.51%), Bellevue Group AG (3.86%) and Price T Rowe Associates Inc. MD (3.23%). Insiders that own company stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal and Yu-Waye Chu.
View institutional ownership trends.

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of FATE stock can currently be purchased for approximately $18.96.

Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $1.84 billion and generates $55.85 million in revenue each year. The biopharmaceutical company earns $-212,150,000.00 in net income (profit) each year or ($3.05) on an earnings per share basis.

The company employs 449 workers across the globe.

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com.